NEW YORK (GenomeWeb) – Microarray-based non-invasive prenatal testing firm CellScape has shut down.
According to its LinkedIn page, the company, which had been headquartered in Newark, Calif., ceased operations in September.
CellScape was founded in 2008 and was developing an NIPT using chromosomal microarrays for detecting fetal aneuploidies, as well as genetic disorders that generally have required invasive methods. In 2013, company officials told GenomeWeb Daily News that the firm planned to launch its test called Clarity in the second half of this year. That target date was later pushed back to 2015.
According to its LinkedIn page, CellScape had between 11 and 50 employees. Its founders were Karen Drexler, Bhairavi Parikh, and James Stone.